Gene dosage and mutational analyses of EGFR in oligodendrogliomas

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 209-215

  Franco Hernandez, Carmen ^a   Martinez Glez, Victor ^a   Alonso, M Eva ^a   De Campos, Jose M ^b   Isla, Alberto ^a   Vaquero, Jesus ^c   Gutierrez, Manuel ^a   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Amplification RT PCR; EGFR; Multiplex ligation dependent probe amplification; Mutation; Oligodendroglioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PRIMER DNA;

AMINO ACID SUBSTITUTION; ARTICLE; BIOPSY; BRAIN TUMOR; EXON; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; BIOPSY; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; EXONS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 39049180584     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.209     Document Type: Article

References (34)

1. Paleologos NA, MacDonald DR and Vick NA: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53: 1141-1143, 1999.
2. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, and Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175-1190, 1994.
3. Bello MJ, Leone PE, Vaquero J, De Campos JM, Kusak ME, Sarasa JL, Pestana A and Rey JA: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64: 207-210, 1995.
4. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, De Pinho R and Israel MA: Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63: 1589-1595, 2003.
5. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002.
6. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984.
7. Theroux SJ, Latour DA, Stanley K, Raden DL and Davis RJ: Signal transduction by the epidermal growth factor receptor is attenuated by a COOH-terminal domain serine phosphorylation site. J Biol Chem 267: 16620-16626, 1992.
8. Reiter JL and Maihle NJ: A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res 24: 4050-4056, 1996.
9. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37: 9-15, 2001.
10. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A and Hidalgo M: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64: 9139-9143, 2004.
11. Rey JA, Bello MJ, Jimenez-Lara AM, Vaquero J, Kusak ME, De Campos JM, Sarasa JL and Pestana A: Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51: 703-706, 1992.
12. Arjona D, Bello MJ, Alonso ME, Aminoso C, Isla A, De Campos JM, Sarasa JL, Gutierrez M, Villalobo A and Rey JA: Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol 31: 384-394, 2005.
13. Alonso ME, Bello MJ, Arjona D, Martinez-Glez V, De Campos JM, Isla A, Kusak E, Vaquero J, Gutierrez M, Sarasa JL and Rey JA: Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. Am J Clin Pathol 123: 900-906, 2005. (Pubitemid 40740690)
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F and Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57, 2002.
15. Malden LT, Novak U, Kaye AH and Burgess AW: Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48: 2711-2714, 1988.
16. Rey JA, Bello MJ, De Campos JM, Kusak ME and Moreno S: Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet Cytogenet 29: 223-237, 1987.
17. Bello MJ, De Campos JM, Kusak ME, Vaquero J, Sarasa JL, Petana A and Rey JA: Ascertainment of chromosome 7 gains in malignant gliomas by cytogenetic and RFLP analyses. Cancer Genet Cytogenet 72: 55-58, 1994. (Pubitemid 24161929)
18. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 25: 1-7, 2005.
19. Rasheed BK, Wiltshire RN, Bigner SH and Bigner DD: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11: 162-167, 1999.
20. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR and Bigner DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4: 148-158, 1998.
21. Sugawa N, Ekstrand AJ, James CD and Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87: 8602-8606, 1990.
22. Schwechheimer K, Huang S and Cavenee WK: EGFR gene amplification rearrangement in human glioblastomas. Int J Cancer 62: 145-148, 1995.
23. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998.
24. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G and Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257, 1996.
25. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
26. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000.
27. Arjona D, Bello MJ and Rey JA: EGFR intragenic loss and gene amplification in astrocytic gliomas. Cancer Genet Cytogenet 164: 39-43, 2006.
28. Etienne-Grimaldi MC, Pereira S, Magne N, Formento JL, Francoual M, Fontana X, Demard F, Dassonville O, Poissonnet G, Santini J, Bendasoun RJ and Szepetowski P: Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 16: 934-941, 2005.
29. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T: Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36: 1127-1134, 2005. (Pubitemid 41443266)
30. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
31. Bianco R, Melisi D, Ciardiello F and Tortora G: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42: 290-294, 2006.
32. Felip E and Rosell R: Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today 42: 147-156, 2006.
33. Buter J and Giaccone G: EGFR inhibitors in lung cancer. Oncology 19: 1707-1711, 2005.
34. Dowell JE: Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. Am J Med Sci 331: 139-149, 2006.